TITLE

Aspirin was cost-effective for primary prevention of cardiovascular events in older women at moderate risk

PUB. DATE
July 2007
SOURCE
ACP Journal Club;Jul/Aug2007, Vol. 147 Issue 1, p24
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article cites a research study conducted to determine whether aspirin is cost-effective for primary prevention of cardiovascular (CV) events in women. The study used cost-utility analysis using a Markov model from the perspective of a third-party payer and a lifetime time horizon. It was found in the base-case analysis, aspirin use in women at moderate risk for CV events led to a cost-utility ratio of $13 300 per quality-adjusted life-year gained.
ACCESSION #
25913669

 

Related Articles

  • Aspirin was cost-effective for primary prevention of cardiovascular events in older women at moderate risk: COMMENTARY. Hillegass, William B.; Dorfman, Todd A. // ACP Journal Club;Jul/Aug2007, Vol. 147 Issue 1, p24 

    The article presents the authors' comments on a research study conducted by M. Pignone and his colleagues to determine the cost-effectiveness of aspirin for primary prevention of cardiovascular events in older women at moderate risk. The authors say that Pignone and colleagues examined the...

  • Aspirin + PPI of value in preventing CVD?  // PharmacoEconomics & Outcomes News;6/30/2007, Issue 531, p8 

    The article reports on two studies which found the cost effectiveness of combining proton pump inhibitor (PPI) therapy with low-dose aspirin for the treatment of patients at risk of developing cardiovascular disease, compared with treatment with aspirin alone. Each study used a Markov model to...

  • Picotamide likely cost effective vs aspirin for preventing CV events.  // PharmacoEconomics & Outcomes News;1/27/2007, Issue 520, p8 

    The article reports on the cost effectiveness of picotamide in preventing cardiovascular events among patient with diabetes and peripheral arterial disease. According to study conducted by researchers from Italy, they created a Markov model to determine the cost effectiveness of lifetime...

  • Aspirin did not prevent vascular events or mortality in adults with a low ankle-brachial index. Burden, A.C. Felix // ACP Journal Club;6/15/2010, Vol. 152 Issue 6, p10 

    The article offers information on the clinical trial conducted on the use of the drug aspirin in adult patients with low ankle brachial index to reduce cardiovascular disease (CV) events or mortality. The trial studied 3350 patients of 50-75 years of age suffering from low ankle brachial index,...

  • Aspirin prophylaxis dominates for AVG patency in haemodialysis.  // PharmacoEconomics & Outcomes News;Nov2013, Issue 691, p5 

    The article discusses the results of a study in the U.S. which show the effectiveness of aspirin monotherapy to prolong primary arteriovenous graft (AVG) patency in hemodialysis patients than extended-release dipyridamole (ERDP) plus low-dose aspirin.

  • Aspirin Prevents Stroke, but Not Cardiovascular Disease, in Women. Ebell, Mark // American Family Physician;8/1/2005, Vol. 72 Issue 3, p502 

    Discusses research being done on the efficacy of aspirin in the primary prevention of cardiovascular disease in women. Reference to a study by P. M. Ridker and colleagues published in the March 31, 2005 issue of "New England Journal of Medicine"; Medical background of the women patients in the...

  • Aspirin appears to protect men and women differently. Chambers, Christopher V.; Russell, John J. // Patient Care;May2005, Vol. 39 Issue 5, p65 

    Provides information on a randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. Primary outcome of the trial; Comparison between the aspirin group and the placebo group; Effect of low-dose aspirin on stroke risk in women.

  • What the 2011 10Q Report means for women's cardiovascular health. Wenger, Nanette K. // Endocrine Today;Oct2011, Vol. 9 Issue 10, p4 

    The article discusses the "2011 10Q Report: Advancing Women's Heart Health Through Improved Research, Diagnosis, and Treatment," which explored the issues related to cardiovascular (CV) care for women in the U.S.

  • Expanded Aspirin Use For Primary Prevention.  // Medical Economics;12/9/2002, Vol. 79 Issue 23, p35 

    Discusses expanded uses of aspirin in primary prevention of cardiovascular events not yet approved by the U.S. Food & Drug Administration. Aspirin therapy guidelines; Target patients.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics